ITRM20030149A0 - Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico. - Google Patents

Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico.

Info

Publication number
ITRM20030149A0
ITRM20030149A0 IT2003RM000149A ITRM20030149A ITRM20030149A0 IT RM20030149 A0 ITRM20030149 A0 IT RM20030149A0 IT 2003RM000149 A IT2003RM000149 A IT 2003RM000149A IT RM20030149 A ITRM20030149 A IT RM20030149A IT RM20030149 A0 ITRM20030149 A0 IT RM20030149A0
Authority
IT
Italy
Prior art keywords
smad7
odn
antisense oligonucleotides
medical field
medical
Prior art date
Application number
IT2003RM000149A
Other languages
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Giuliani Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of ITRM20030149A0 publication Critical patent/ITRM20030149A0/it
Priority to IT2003RM000149 priority Critical patent/ITRM20030149A1/it
Application filed by Giuliani Spa filed Critical Giuliani Spa
Priority to DE602004018288T priority patent/DE602004018288D1/de
Priority to JP2006507636A priority patent/JP4559411B2/ja
Priority to MXPA05010549A priority patent/MXPA05010549A/es
Priority to CA2520541A priority patent/CA2520541C/en
Priority to AT04718384T priority patent/ATE417102T1/de
Priority to EP04718384A priority patent/EP1608753B1/en
Priority to PL04718384T priority patent/PL1608753T3/pl
Priority to CNB2004800123449A priority patent/CN100556461C/zh
Priority to SI200431026T priority patent/SI1608753T1/sl
Priority to DK04718384T priority patent/DK1608753T3/da
Priority to PCT/IT2004/000117 priority patent/WO2004087920A1/en
Priority to ES04718384T priority patent/ES2316970T3/es
Priority to NZ542718A priority patent/NZ542718A/en
Priority to KR1020057018531A priority patent/KR100822972B1/ko
Priority to RU2005133711A priority patent/RU2339697C2/ru
Priority to PT04718384T priority patent/PT1608753E/pt
Priority to AU2004225666A priority patent/AU2004225666B2/en
Priority to US10/551,643 priority patent/US7700757B2/en
Publication of ITRM20030149A1 publication Critical patent/ITRM20030149A1/it
Priority to NO20054861A priority patent/NO334022B1/no
Priority to US11/501,756 priority patent/US20070042985A1/en
Priority to US12/264,058 priority patent/US7807818B2/en
Priority to CY091100264T priority patent/CY1108870T1/el
Priority to JP2010126606A priority patent/JP5039172B2/ja
Priority to US12/854,558 priority patent/US8106182B2/en
Priority to US13/332,134 priority patent/US20120136043A1/en
Priority to US13/836,634 priority patent/US8648186B2/en
Priority to US14/144,029 priority patent/US9006418B2/en
Priority to US14/266,343 priority patent/US8907078B2/en
Priority to US14/613,181 priority patent/US9096854B1/en
Priority to US14/685,091 priority patent/US9279126B2/en
Priority to US14/815,339 priority patent/US9382541B2/en
Priority to US15/063,077 priority patent/US9605264B2/en
Priority to US15/201,061 priority patent/US9518264B2/en
Priority to US15/355,329 priority patent/US10036022B2/en
Priority to US15/457,631 priority patent/US9951334B2/en
Priority to US15/928,494 priority patent/US10738309B2/en
Priority to US16/046,389 priority patent/US10633660B2/en
Priority to US16/836,213 priority patent/US20200325480A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT2003RM000149 2003-04-02 2003-04-02 Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico ITRM20030149A1 (it)

Priority Applications (39)

Application Number Priority Date Filing Date Title
IT2003RM000149 ITRM20030149A1 (it) 2003-04-02 2003-04-02 Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US10/551,643 US7700757B2 (en) 2003-04-02 2004-03-08 Antisense oligonucleotides (ODN) against Smad7 and uses in medical field thereof
CNB2004800123449A CN100556461C (zh) 2003-04-02 2004-03-08 抗Smad7的反义寡核苷酸(ODN)及其在医药领域中的用途
DK04718384T DK1608753T3 (da) 2003-04-02 2004-03-08 Antisens-oligonukleotider (ODN) mod Smad7 og anvendelser deraf i det medicinske felt
MXPA05010549A MXPA05010549A (es) 2003-04-02 2004-03-08 Oligonucleotidos (odn) antisense contra smad7 y su utilizacion en el campo medico.
CA2520541A CA2520541C (en) 2003-04-02 2004-03-08 Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
AT04718384T ATE417102T1 (de) 2003-04-02 2004-03-08 Antisense-oligonukleotide (odn) gegen smad7 und ihre verwendung in der medizin
EP04718384A EP1608753B1 (en) 2003-04-02 2004-03-08 Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof
PL04718384T PL1608753T3 (pl) 2003-04-02 2004-03-08 Antysensowne oligonukleotydy (ODN) przeciw Smad7 i ich zastosowania w dziedzinie medycyny
DE602004018288T DE602004018288D1 (de) 2003-04-02 2004-03-08 Antisense-oligonukleotide (odn) gegen smad7 und ihre verwendung in der medizin
SI200431026T SI1608753T1 (sl) 2003-04-02 2004-03-08 Protismerni oligonukleotidni zaäśetniki za smad7 in njihova uporaba v medicini
JP2006507636A JP4559411B2 (ja) 2003-04-02 2004-03-08 Ｓｍａｄ７に対するアンチセンスオリゴヌクレオチド（ＯＤＮ）及びその医療分野での使用
PCT/IT2004/000117 WO2004087920A1 (en) 2003-04-02 2004-03-08 Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof
ES04718384T ES2316970T3 (es) 2003-04-02 2004-03-08 Oligonucleotidos (odn) antisentido contra smad7 y usos en el campo medico de los mismos.
NZ542718A NZ542718A (en) 2003-04-02 2004-03-08 Antisense oligonucleotides (ODN) against Smad7 and uses in the medical field
KR1020057018531A KR100822972B1 (ko) 2003-04-02 2004-03-08 Ｓｍａｄ7에 대한 안티센스 올리고뉴클레오티드(ＯＤＮ) 및의학 분야에서 이의 용도
RU2005133711A RU2339697C2 (ru) 2003-04-02 2004-03-08 АНТИСМЫСЛОВЫЕ ОЛИГОНУКЛЕОТИДЫ (ODN) К Smad7 И ИХ ПРИМЕНЕНИЕ В ОБЛАСТИ МЕДИЦИНЫ
PT04718384T PT1608753E (pt) 2003-04-02 2004-03-08 Oligonucleótidos anti-sentido (odn) contra smad7 e utilizações destes no campo médico
AU2004225666A AU2004225666B2 (en) 2003-04-02 2004-03-08 Antisense oligonucleotides (ODN) against Smad7 and uses in medical field thereof
NO20054861A NO334022B1 (no) 2003-04-02 2005-10-20 Antisens oligonukleotider (ODN) mot SMAD7 og anvendelser derav i det medisinske området
US11/501,756 US20070042985A1 (en) 2003-04-02 2006-08-10 Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US12/264,058 US7807818B2 (en) 2003-04-02 2008-11-03 Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
CY091100264T CY1108870T1 (el) 2003-04-02 2009-03-10 Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους
JP2010126606A JP5039172B2 (ja) 2003-04-02 2010-06-02 Ｓｍａｄ７に対するアンチセンスオリゴヌクレオチド（ＯＤＮ）及びその医療分野での使用
US12/854,558 US8106182B2 (en) 2003-04-02 2010-08-11 Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US13/332,134 US20120136043A1 (en) 2003-04-02 2011-12-20 Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
US13/836,634 US8648186B2 (en) 2003-04-02 2013-03-15 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US14/144,029 US9006418B2 (en) 2003-04-02 2013-12-30 Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US14/266,343 US8907078B2 (en) 2003-04-02 2014-04-30 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US14/613,181 US9096854B1 (en) 2003-04-02 2015-02-03 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US14/685,091 US9279126B2 (en) 2003-04-02 2015-04-13 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US14/815,339 US9382541B2 (en) 2003-04-02 2015-07-31 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US15/063,077 US9605264B2 (en) 2003-04-02 2016-03-07 Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US15/201,061 US9518264B2 (en) 2003-04-02 2016-07-01 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US15/355,329 US10036022B2 (en) 2003-04-02 2016-11-18 Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US15/457,631 US9951334B2 (en) 2003-04-02 2017-03-13 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US15/928,494 US10738309B2 (en) 2003-04-02 2018-03-22 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US16/046,389 US10633660B2 (en) 2003-04-02 2018-07-26 Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US16/836,213 US20200325480A1 (en) 2003-04-02 2020-03-31 Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2003RM000149 ITRM20030149A1 (it) 2003-04-02 2003-04-02 Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico

Publications (2)

Publication Number Publication Date
ITRM20030149A0 true ITRM20030149A0 (it) 2003-04-02
ITRM20030149A1 ITRM20030149A1 (it) 2004-10-03

Family

ID=29765741

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2003RM000149 ITRM20030149A1 (it) 2003-04-02 2003-04-02 Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico

Country Status (21)

Country Link
US (18) US7700757B2 (it)
EP (1) EP1608753B1 (it)
JP (2) JP4559411B2 (it)
KR (1) KR100822972B1 (it)
CN (1) CN100556461C (it)
AT (1) ATE417102T1 (it)
AU (1) AU2004225666B2 (it)
CA (1) CA2520541C (it)
CY (1) CY1108870T1 (it)
DE (1) DE602004018288D1 (it)
DK (1) DK1608753T3 (it)
ES (1) ES2316970T3 (it)
IT (1) ITRM20030149A1 (it)
MX (1) MXPA05010549A (it)
NO (1) NO334022B1 (it)
NZ (1) NZ542718A (it)
PL (1) PL1608753T3 (it)
PT (1) PT1608753E (it)
RU (1) RU2339697C2 (it)
SI (1) SI1608753T1 (it)
WO (1) WO2004087920A1 (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456380B1 (en) * 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
CA3085272A1 (en) * 2008-11-13 2010-05-20 Nogra Pharma Limited Antisense compositions and methods of making and using same
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
SG10201403841QA (en) 2009-07-06 2014-09-26 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP2630241B1 (en) * 2010-10-22 2018-10-17 CuRNA, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
JP6389122B2 (ja) * 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
AU2013249191B2 (en) * 2012-04-18 2019-01-03 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
WO2014010718A1 (ja) 2012-07-13 2014-01-16 株式会社新日本科学 キラル核酸アジュバント
EP3812370A1 (en) 2012-07-13 2021-04-28 Wave Life Sciences Ltd. Asymmetric auxiliary group
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2014229985B2 (en) * 2013-03-15 2018-12-13 Nogra Pharma Limited Methods of treating colorectal cancer
WO2014198890A1 (en) * 2013-06-13 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
MA39963A (fr) * 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
WO2015011694A2 (en) 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US9688993B2 (en) 2015-02-13 2017-06-27 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CA2991052A1 (en) 2015-07-02 2017-01-05 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US20180289692A1 (en) * 2015-09-30 2018-10-11 Celgene Corporation Tlr modulators and methods of use
WO2017147276A1 (en) * 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition
EP3554345A1 (en) * 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
WO2019133949A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Therapeutics of ptd-smad7 fusion proteins
US10768615B2 (en) * 2018-02-26 2020-09-08 Sanskar Agrawal System and method for automated hospital beds

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096722A (en) 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
ATE162198T1 (de) 1992-07-27 1998-01-15 Hybridon Inc Oligonukleotid alkylphosphonothiate
US6884787B2 (en) 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
DK0667148T3 (da) 1992-11-06 2002-07-22 Hisamitsu Pharmaceutical Co Peroralt farmaceutisk præparat, der udløses i den nedre del af mavetarmkanalen
US20020177568A1 (en) 1992-12-07 2002-11-28 Stinchcomb Dan T. Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
EP0904277A4 (en) * 1996-02-16 2003-01-22 Millennium Pharm Inc COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CARDIOVASCULAR DISEASES
US6099823A (en) 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5783566A (en) 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JPH10295381A (ja) 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
CA2290040A1 (en) 1997-05-20 1998-11-26 Ludwig Institute For Cancer Research Smad7 and uses thereof
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
EP1066323A1 (en) 1998-03-27 2001-01-10 Eli Lilly And Company Treatment and prevention of vascular disease
JPH11335269A (ja) 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
WO1999060012A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6159397A (en) * 1998-11-18 2000-12-12 Eyecity.Com, Inc. Translucent eyewear lenses and method of manufacture therefor
US5962673A (en) 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US6479465B2 (en) 1999-03-24 2002-11-12 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating colitis using STAT-4 anti-sense oligonucleotides
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US20020147140A1 (en) 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055301A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
IL151345A0 (en) * 2000-02-23 2003-04-10 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001070955A2 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
CA2411601A1 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002002807A2 (en) 2000-06-30 2002-01-10 Epigenomics Ag Diagnosis of diseases associated with cell signalling
US20030134324A1 (en) 2000-08-07 2003-07-17 Munger William E. Identifying drugs for and diagnosis of Benign Prostatic Hyperplasia using gene expression profiles
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20030087259A1 (en) 2001-04-18 2003-05-08 Clancy Brian M. Methods and compositions for regulating bone and cartilage formation
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
JP2003135075A (ja) 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1581634A4 (en) 2002-12-10 2006-10-25 Scripps Research Inst METHOD FOR TREATING DRUG ADDICTION AND SCREENING PHARMACEUTICALS THEREFOR
WO2004083389A2 (en) 2003-03-13 2004-09-30 Exelixis Inc. Mbcats as modifiers of the beta-catenin pathway and methods of use
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20040265833A1 (en) 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
AU2004262369A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
ITRM20030393A1 (it) 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
FR2862659B1 (fr) 2003-11-21 2006-02-10 Pasteur Institut Genome de legionella pneumophila souche paris- applications diagnostiques et epidemiologiques
WO2005077403A1 (en) 2004-02-04 2005-08-25 Stryker Corporation Therapeutic methods using smads
WO2005084712A2 (en) 2004-02-27 2005-09-15 Antisense Pharma Gmbh Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US20080300147A1 (en) 2004-03-26 2008-12-04 Nasser Chegini Detection and Treatment of Fibrotic Disorders
WO2007022642A2 (en) 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
US20080312093A1 (en) 2005-11-04 2008-12-18 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
EP2012815A4 (en) 2006-04-14 2009-12-09 Massachusetts Inst Technology IDENTIFICATION AND MODULATION OF MOLECULAR PATHS FOR PROCESSING NEURONAL PLASTICITY
EP2049691A4 (en) 2006-07-26 2010-06-16 Genizon Biosciences Inc SUSCEPTIBILITY TREASURES FOR MORBUS CROHN
WO2008046964A2 (en) 2006-10-16 2008-04-24 Panu Jaakkola Novel useful inhibitors
WO2009151600A2 (en) 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
CA3085272A1 (en) 2008-11-13 2010-05-20 Nogra Pharma Limited Antisense compositions and methods of making and using same
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
AU2013249191B2 (en) 2012-04-18 2019-01-03 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2014229985B2 (en) 2013-03-15 2018-12-13 Nogra Pharma Limited Methods of treating colorectal cancer
MA39963A (fr) 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US20210207143A1 (en) 2016-02-24 2021-07-08 Nogra Pharma Limited Methods of Treating Celiac Disease Using SMAD7 Inhibition
JP2020503327A (ja) 2016-12-30 2020-01-30 ノグラ ファーマ リミテッド Ｓｍａｄ７アンチセンスオリゴヌクレオチドの組成物および乾癬を処置するまたは予防する方法

Also Published As

Publication number Publication date
US9605264B2 (en) 2017-03-28
US20070042985A1 (en) 2007-02-22
US8648186B2 (en) 2014-02-11
RU2005133711A (ru) 2006-05-10
ITRM20030149A1 (it) 2004-10-03
KR20050118705A (ko) 2005-12-19
EP1608753B1 (en) 2008-12-10
CY1108870T1 (el) 2014-07-02
EP1608753A1 (en) 2005-12-28
US7807818B2 (en) 2010-10-05
US20130203839A1 (en) 2013-08-08
US9279126B2 (en) 2016-03-08
US9518264B2 (en) 2016-12-13
NO20054861L (no) 2005-10-20
US20150218561A1 (en) 2015-08-06
US20100317719A1 (en) 2010-12-16
US9096854B1 (en) 2015-08-04
CA2520541C (en) 2012-05-08
SI1608753T1 (sl) 2009-04-30
JP2006521815A (ja) 2006-09-28
DK1608753T3 (da) 2009-04-14
US20160177306A1 (en) 2016-06-23
US20170253880A1 (en) 2017-09-07
US10738309B2 (en) 2020-08-11
RU2339697C2 (ru) 2008-11-27
AU2004225666A1 (en) 2004-10-14
MXPA05010549A (es) 2006-05-25
NO334022B1 (no) 2013-11-18
ATE417102T1 (de) 2008-12-15
JP2010193906A (ja) 2010-09-09
JP5039172B2 (ja) 2012-10-03
US20070167385A1 (en) 2007-07-19
KR100822972B1 (ko) 2008-04-17
CA2520541A1 (en) 2004-10-14
US20190211336A1 (en) 2019-07-11
US8907078B2 (en) 2014-12-09
US9382541B2 (en) 2016-07-05
AU2004225666B2 (en) 2008-07-10
US20150337312A1 (en) 2015-11-26
US20150211011A1 (en) 2015-07-30
AU2004225666A2 (en) 2004-10-14
US20160304876A1 (en) 2016-10-20
US9951334B2 (en) 2018-04-24
PT1608753E (pt) 2009-02-16
US7700757B2 (en) 2010-04-20
US20200181622A1 (en) 2020-06-11
US9006418B2 (en) 2015-04-14
NZ542718A (en) 2007-04-27
WO2004087920A1 (en) 2004-10-14
PL1608753T3 (pl) 2009-06-30
CN1788086A (zh) 2006-06-14
US10633660B2 (en) 2020-04-28
US20120136043A1 (en) 2012-05-31
US10036022B2 (en) 2018-07-31
US8106182B2 (en) 2012-01-31
CN100556461C (zh) 2009-11-04
US20140256788A1 (en) 2014-09-11
JP4559411B2 (ja) 2010-10-06
US20140142163A1 (en) 2014-05-22
DE602004018288D1 (de) 2009-01-22
US20090156539A1 (en) 2009-06-18
ES2316970T3 (es) 2009-04-16
US20180030450A1 (en) 2018-02-01
US20200325480A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
ITRM20030149A0 (it) Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico.
ITRM20020253A0 (it) Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
ITMI20021972A1 (it) Dispositivo per uso medico.
ITRE20050009A1 (it) Dispositivo medico antireflusso basato sull'azione di magneti
ITUD20020210A1 (it) Procedimento e dispositivo per la piegatura di elementi,
ITMI20030211A1 (it) Modulo integrato di trattamento sangue ed apparecchiatura per il trattamento extracorporeo di sangue.
AU2003242678A8 (en) Antisense oligonucleotides against pim1
IL158600A0 (en) Ache antisense deoxyoligonucleotide as an anti-inflammatory agent
ITRM20030393A1 (it) Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
IS7538A (is) Prógestagena skammta einingar.
ITTO20030218A1 (it) Sonda, in particolare per cavita' tubolari.
ITMI20030823A1 (it) Processo di preparazione di alcossi e arilossifenoli.
ES1055675Y (es) Jeringa perfeccionada.
ITMI20031072A1 (it) Ceramica biodegradabile per uso medico.
FR2878727B3 (fr) Lave-vaisselle, notamment pour instruments medicaux
ES1051002Y (es) Jeringa perfeccionada.
NO20052979D0 (no) Propargyl-trifluormetoksy-amino-benzotiazolderivater.
GB2420345B (en) 3-alpha-glycosyl alpha, alpha-trehaloses their preparation and use
ITTO20030222A1 (it) Dispositivo per la generazione casuale di numeri e/o codici.
ES1054082Y (es) Servilletero perfeccionado.
ITRM20030026U1 (it) Dispositivo di ancoraggio, ad assetto variabile, per kitesurf o windsu rf.
ES1056305Y (es) Expositor de toallas, perfeccionado.
ITPD20030111A1 (it) Reggimensola perfezionato.
ITMI20022198A1 (it) Metodo per la rilevazione di fitovirus in piante mediante rna antisenso e piante trasformate.
ITTV20030144A1 (it) Erogatore per doccia particolarmente ad uso ritemprante o terapeutico.